Staff Profiles

Tom Bumol, Ph.D.

Executive Vice President, Director of Immunology

Thomas F. Bumol, Ph.D., is the Executive Director of the Allen Institute for Immunology in Seattle, Washington, a position he assumed on March 1, 2018.  He was the Senior Vice-President of the Biotechnology and Immunology Research component at Lilly Research Laboratories, and the Site Head of Lilly’s Biotechnology Center of San Diego, which included the former Applied Molecular Evolution subsidiary of Lilly Research Laboratories and early clinical development for immunology assets from Lilly (phase I and phase II) until his retirement in December of 2017.

A native of Detroit, Michigan, Bumol received his B.S. degree in microbiology with distinction from the University of Michigan in 1975. He subsequently completed his Ph.D. in microbiology-immunology from the University of Minnesota in 1980. Bumol was the recipient of a Damon Runyon-Walter Winchell Cancer Research Fellowship for his postdoctoral studies in the Department of Molecular Immunology at Scripps Clinic and Research Foundation in La Jolla, California from 1980-1982.  He joined Lilly Research Laboratories as a Senior Immunologist in 1982 where he remained for his career of over 35 years until his retirement. Bumol has over 50 publications and reviews, 8 issued U.S. patents and his team and collaborators have nominated over 100 molecules into clinical development including dulaglutide (Trulicity), ixekizumab (Taltz), galcanezumab (Emgality) and mirikizumab while at Lilly Research Laboratories. In addition, through strategic alliances his teams helped develop and support ReoPro with Centocor and baricitinib (Olumiant) with Incyte. 

He serves on the University of Michigan Technology Transfer National Advisory Board, and Bumol continues to advise Lilly Ventures and several start-up biotechnology companies.

Selected Publications

Unifying researchers and clinicians to eliminate ex vivo artifacts in human immune system studies

June 28, 2021

Bumol T, Coffey E, Meijer P, Li X, Skene P, Torgerson T.

Multimodal analysis for human ex vivo studies shows extensive molecular changes from delays in blood processing

May 21, 2021

Savage AK, Gutschow MV, Chiang T, Henderson K, Green R, Chaudhari M, Swanson E, Heubeck AT, Kondza N, Burley KC, Genge PC, Lord C, Smith T, Thomson Z, Beaubien A, Johnson E, Goldy J, Bolouri H, Buckner J, Meijer P, Coffey EM, Skene PJ, Torgerson TR, Li XJ, Bumol TF

Simultaneous trimodal single-cell measurement of transcripts, epitopes, and chromatin accessibility using TEA-seq

April 9, 2021

Swanson E, Lord C, Reading J, Heubeck AT, Genge PC, Thomson Z, Weiss MDA, Li X, Savage AK, Green RR, Torgerson TR, Bumol TF, Graybuck LT, Skene PJ

Optimized workflow for human PBMC multiomic immunosurveillance studies

STAR Protocols
November 11, 2021

Genge PC, Roll CR, Heubeck AT, Swanson E, Kondza N, Lord C, Weiss M, Hernandez V, Phalen C, Thomson Z, Torgerson TR, Skene PJ, Bumol TF, Reading J